Healthcare Industry News: Imitrex
News Release - November 15, 2006
Cobalt Announces Settlement of Imitrex(R) Litigation With GlaxoSmithKline
BONITA SPRINGS, Fla., Nov. 15 (HSMN NewsFeed) -- Cobalt Laboratories Inc. (Cobalt), on behalf of its affiliate Cobalt Pharmaceuticals Inc., announced today that is has settled patent litigation with GlaxoSmithKline relating to sumatriptan succinate tablets, the generic version of GlaxoSmithKline's Imitrex® tablets.The terms of the settlement, which remain subject to government review, provide that Cobalt may distribute a generic version of sumatriptan succinate tablets (in the 25 mg, 50 mg and 100 mg strengths) in the United States with an expected launch date early in the first quarter, 2009.
Additional terms of the settlement agreement were not disclosed.
GlaxoSmithKline's Imitrex® tablets, which are indicated for the acute treatment of migraine attacks in adults, had U.S. sales of $890 million for the 12 month period ending June, 2006 according to IMS.
About Cobalt Laboratories
Cobalt Laboratories is the United States subsidiary of Arrow Pharmaceuticals Inc., an emerging global pharmaceutical company. The companies are vertically integrated and develop, manufacture and market pharmaceutical products. Cobalt benefits from Arrow's global experience and dedication to R&D and offers a variety of generic pharmaceuticals domestically. Cobalt focuses on building unique partnerships, innovative thinking, and exceptional customer service. It is well positioned for growth with a diverse pipeline portfolio of multi-source and First-To-File ANDAs.
Source: Cobalt Laboratories
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
